HC Wainwright Reiterates Buy Rating for Enlivex Therapeutics (NASDAQ:ENLV)

HC Wainwright reissued their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a report released on Tuesday, Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

Enlivex Therapeutics Price Performance

Shares of ENLV opened at $1.32 on Tuesday. Enlivex Therapeutics has a 1-year low of $1.15 and a 1-year high of $4.59. The company has a 50-day moving average of $3.26 and a 200 day moving average of $2.54. The firm has a market capitalization of $24.51 million, a price-to-earnings ratio of -0.85 and a beta of 1.02.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.